IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia

Leukemia

Volumn 29, Issue 2, 2015, Pages 415-422

  Pegram, H J ^a   Purdon, T J ^a   Van Leeuwen, D G ^a   Curran, K J ^a   Giralt, S A ^a,b   Barker, J N ^a,b   Brentjens, R J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; CYTOKINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LEUKEMIA; CANCER IMMUNOTHERAPY; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE FREE SURVIVAL; EFFECTOR CELL; GRAFT VERSUS LEUKEMIA EFFECT; IN VITRO STUDY; IN VIVO STUDY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL EXPANSION; T LYMPHOCYTE; UMBILICAL CORD BLOOD; UMBILICAL CORD BLOOD DERIVED T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; B LYMPHOCYTE; CYTOLOGY; DISEASE COURSE; FETUS BLOOD; FLOW CYTOMETRY; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; RECURRENT DISEASE; SCID MOUSE; TRANSGENE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD19; B-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FETAL BLOOD; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERLEUKIN-12; INTERLEUKIN-15; MICE; MICE, SCID; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; T-LYMPHOCYTES; TRANSGENES;

EID: 84922544653     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.215     Document Type: Article

References (29)

1. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653-660.
2. Ponce DM, Zheng J, Gonzales AM, Lubin M, Heller G, Castro-Malaspina H et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1316-1326.
3. Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 2010; 115: 1843-1849.
4. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116: 4693-4699.
5. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versusleukemia effect in recipients of 2 units. Blood 2009; 114: 4293-4299.
6. Marks DI, Woo KA, Zhong X, Appelbaum FR, Bachanova V, Barker JN et al. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica 2014; 99: 322-328.
7. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007; 13: 5426-5435.
8. Wang LX, Westwood JA, Moeller M, Duong CP, Wei WZ, Malaterre J et al. Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res 2010; 70: 9591-9598.
9. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118: 4817-4828.
10. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5: 177ra38.
11. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
12. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119: 2709-2720.
13. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013; 122: 4129-4139.
14. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003; 9: 279-286.
15. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999; 1: 123-127.
16. Okas M, Gertow J, Uzunel M, Karlsson H, Westgren M, Karre K et al. Clinical expansion of cord blood-derived T cells for use as donor lymphocyte infusion after cord blood transplantation. J Immunother 2010; 33: 96-105.
17. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M et al. Tumortargeted T cells modi fied to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119: 4133-4141.
18. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611-1618.
19. Serrano LM, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, Kim D et al. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood 2006; 107: 2643-2652.
20. Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ et al. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 2010; 115: 2695-2703.
21. Robinson KL, Ayello J, Hughes R, van de Ven C, Issitt L, Kurtzberg J et al. Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation. Exp Hematol 2002; 30: 245-251.
22. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009; 114: 1958-1967.
23. Smith KM, Tonon J, Evans KL, Lubin MN, Byam C, Ponce DM et al. Analysis of 402 cord blood units to assess factors infl uencing infused viable CD34+ cell dose: the critical determinant of engraftment. Blood 2013; 122: 296.
24. Hsu C, Jones SA, Cohen CJ, Zheng Z, Kerstann K, Zhou J et al. Cytokineindependent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 2007; 109: 5168-5177.
25. Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 2001; 193: 219-231.
26. Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther 2010; 21: 75-86.
27. Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem 2010; 17: 3297-3302.
28. Davis CC, Marti LC, Sempowski GD, Jeyaraj DA, Szabolcs P. Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation. Cancer Res 2010; 70: 5249-5258.
29. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365: 1673-1683.